Themis Medicare Limited (THEMISMED) Fair Value & Analysis
Healthcare · IN · Market cap ₹11.1B
Fair value as of: Jul 3, 2026
From 13 valuation models · updated today
Share price +8.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹66.07 – ₹142.46 · fair‑value band ₹155.47 – ₹288.05 · the ₹118.59 price screens below the ₹221.29 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Themis Medicare Limited (THEMISMED) currently trades at ₹118.59, while our model-based Fair Value estimate is ₹221.29 — implying the stock looks roughly 86.6% undervalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Themis Medicare Limited generated revenue of ₹3.4B at a net margin of 0.3%. Revenue grew 6.7% year over year. It earns a return on equity of 0.3%. Net debt stands at ₹909M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammatory, anti-allergic and appetite stimulant, anticoagulant, antifibrolytic, antimalarial, anti-muscarinic, antioxidant, calcium, cardiovascular, corticosteroid, electrolytes, expectorant, hematinic, hemostatic agent, hemostatic agent with anesthetic, hormones, immunomodulator with anti-viral, muscle relaxant, narcotic analgesic, neuropathy, nutraceuticals, PPI, probiotic, reversal for muscle relaxant, sedatives, skeletal muscle relaxant, skeletal muscle relaxant and analgesic and anti-inflammatory, vasodilator, …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Themis Medicare Limited reported revenue of ₹3.4B in FY2026 versus ₹3.9B in FY2022, a compound −3.5%/yr. Reported net income was ₹11.4M in FY2026, compounding −64.6%/yr from FY2022.
Is THEMISMED fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Themis Medicare Limited (THEMISMED) undervalued?
What is the fair value of THEMISMED?
What is the quality score of THEMISMED?
What is the revenue of Themis Medicare Limited (THEMISMED)?
What is the net profit margin of THEMISMED?
Does Themis Medicare Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.